Hip implant maker Zimmer Biomet lowered its annual profit forecast on Wednesday following last month's disruptions to a software platform that was managing some of the company's operations. Zimmer ...

Recommended Reading Exactech implants may oxidize, FDA says, warning surgeons not to use any recalled joints Zimmer Biomet will phase out sales of its CPT Hip System by December due to concerns ...

Zimmer Biomet's sales are up 4% to $1.82 billion. Knee and hip products grew, while 2024 EPS guidance was slightly lowered.

The next two years are expected to be an important time for Zimmer Biomet's growth, CEO Ivan Tornos said in an Oct. 30 quarterly earnings call.

Please view our full advertiser disclosure policy. Anthem Essential Choice PPO Platinum is the best dental insurance plan, based on our in-depth analysis of rates and coverage. While this dental ...

Breast implants don’t cause breast cancer. They don’t raise your chances of breast cancer, either. But research does show that women with breast implants have a higher chance of anaplastic ...

This three year, part-time programme is for dental practitioners who want to improve their skills within the discipline of implant dentistry. This course provides exemplary one to one supervision ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

After reviewing hip implants from the NJR data, the research team found the risk of revision following a hip replacement is influenced by the type of material used in the bearing surface. Bearing ...

A metal hip implant used in thousands of NHS patients will be axed as a result of an increase in bone fractures. The Medicines and Healthcare products Regulatory Agency (MHRA) said the implant ...

Oct 30 (Reuters) - Hip implant maker Zimmer Biomet (ZBH.N), opens new tab lowered its annual profit forecast on Wednesday following last month's disruptions to a software platform that was ...